<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33421065</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1554-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>22</Day></PubDate></JournalIssue><Title>Journal of neuropathology and experimental neurology</Title><ISOAbbreviation>J Neuropathol Exp Neurol</ISOAbbreviation></Journal><ArticleTitle>TDP-43 Vasculopathy in the Spinal Cord in Sporadic Amyotrophic Lateral Sclerosis (sALS) and Frontal Cortex in sALS/FTLD-TDP.</ArticleTitle><Pagination><StartPage>229</StartPage><EndPage>239</EndPage><MedlinePgn>229-239</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jnen/nlaa162</ELocationID><Abstract><AbstractText>Sporadic amyotrophic lateral sclerosis (sALS) and FTLD-TDP are neurodegenerative diseases within the spectrum of TDP-43 proteinopathies. Since abnormal blood vessels and altered blood-brain barrier have been described in sALS, we wanted to know whether TDP-43 pathology also occurs in blood vessels in sALS/FTLD-TDP. TDP-43 deposits were identified in association with small blood vessels of the spinal cord in 7 of 14 cases of sALS and in small blood vessels of frontal cortex area 8 in 6 of 11 FTLD-TDP and sALS cases, one of them carrying a GRN mutation. This was achieved using single and double-labeling immunohistochemistry, and double-labeling immunofluorescence and confocal microscopy. In the sALS spinal cord, P-TDP43 Ser403-404 deposits were elongated and parallel to the lumen, whereas others were granular, seldom forming clusters. In the frontal cortex, the inclusions were granular, or elongated and parallel to the lumen, or forming small globules within or in the external surface of the blood vessel wall. Other deposits were localized in the perivascular space. The present findings are in line with previous observations of TDP-43 vasculopathy in a subset of FTLD-TDP cases and identify this pathology in the spinal cord and frontal cortex in a subset of cases within the sALS/FTLD-TDP spectrum.</AbstractText><CopyrightInformation>&#xa9; 2021 American Association of Neuropathologists, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferrer</LastName><ForeName>Isidro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Department of Pathology and Experimental Therapeutics, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurosciences, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuropathology, Pathologic Anatomy Service, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andr&#xe9;s-Benito</LastName><ForeName>Pol</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Department of Pathology and Experimental Therapeutics, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Neurosciences, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carmona</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Pathology and Experimental Therapeutics, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Network Research Center on Neurodegenerative Diseases (CIBERNED), Institute Carlos III, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assialioui</LastName><ForeName>Abdelilah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>M&#xf3;nica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Initiative for Treatment and Research Initiative to Cure ALS (TRICALS), Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neuropathol Exp Neurol</MedlineTA><NlmUniqueID>2985192R</NlmUniqueID><ISSNLinking>0022-3069</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013116" MajorTopicYN="N">Spinal Cord</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="N">blood supply</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014652" MajorTopicYN="N">Vascular Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Blood vessels</Keyword><Keyword MajorTopicYN="N">Endothelial cells</Keyword><Keyword MajorTopicYN="N">Frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">Pericytes</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>9</Day><Hour>17</Hour><Minute>8</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33421065</ArticleId><ArticleId IdType="pmc">PMC7899266</ArticleId><ArticleId IdType="doi">10.1093/jnen/nlaa162</ArticleId><ArticleId IdType="pii">6075095</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mackenzie IR, Feldman HH.. Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrum. J Neuropathol Exp Neurol 2005;64:730&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">16106222</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al.Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130&#x2013;3</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandmeir NJ, Geser F, Kwong LK, et al.Severe subcortical TDP-43 pathology in sporadic frontotemporal lobar degeneration with motor neuron disease. Acta Neuropathol 2007;115:123&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pubmed">18004574</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Martinez-Lage M, Robinson J, et al.Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 2009;66:180&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2774117</ArticleId><ArticleId IdType="pubmed">19204154</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Hortob&#xe1;gyi T, Okamoto K, et al.Amyotrophic lateral sclerosis, primary lateral sclerosis, and spinal muscular atrophy In: Dickson DW, Weller RO, eds. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders, 2nd edition. Oxford: Wiley-Blackwell; 2011:418&#x2013;33.</Citation></Reference><Reference><Citation>Elman LB, McCluskey L, Grossman M.. Motor neuron disease and frontotemporal lobar degeneration: A tale of two disorders linked to TDP-43. Neurosignals 2008;16:85&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pubmed">18097163</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Prvulovic D, O&#x2019;Dwyer L, et al.On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia. Prog Neurobiol 2011;95:649&#x2013;62</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230745</ArticleId><ArticleId IdType="pubmed">21911035</ArticleId></ArticleIdList></Reference><Reference><Citation>Hortobagyi T, Cairns NJ.. Amyotrophic lateral sclerosis and frontotemporal lobar degeneration In: Kovacs GG, ed. Neuropathology of Neurodegenerative Diseases: A Practical Guide. Cambridge: Cambridge University Press; 2015:209&#x2013;48.</Citation></Reference><Reference><Citation>Takeda T, Seilhean D, Le Ber I, et al.Amygdala TDP43 pathology in frontotemporal degeneration and motor neuron disease. J Neuropathol Exp Neurol 2017;76:800&#x2013;12</Citation><ArticleIdList><ArticleId IdType="pubmed">28859337</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordana MT, Piccinini M, Grifoni S, et al.TDP-43 redistribution is an early event in sporadic amyotrophic lateral sclerosis. Brain Pathol 2010;20:351&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pubmed">19338576</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, Skibinski G, Korb E, et al.Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J. Neurosci 2010;30:639&#x2013;49</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821110</ArticleId><ArticleId IdType="pubmed">20071528</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Jones A, Troakes C, et al.The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol 2012;124:339&#x2013;52</Citation><ArticleIdList><ArticleId IdType="pubmed">22903397</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Truax AC, et al.TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions. J Neuropathol Exp Neurol 2007;66:177&#x2013;83 [Database</Citation><ArticleIdList><ArticleId IdType="pubmed">17356379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mori F, Tanji K, Zhang HX, et al.Maturation process of TDP-43-positive neuronal cytoplasmic inclusions in amyotrophic lateral sclerosis with and without dementia. Acta Neuropathol 2008;116:193&#x2013;203</Citation><ArticleIdList><ArticleId IdType="pubmed">18560845</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Baborie A, Pickering-Brown S, et al.Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: Classification and relation to clinical phenotype. Acta Neuropathol 2006;112:539&#x2013;49</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668618</ArticleId><ArticleId IdType="pubmed">17021754</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampathu DM, Neumann M, Kwong LK, et al.Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol 2006;169:1343&#x2013;52</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780184</ArticleId><ArticleId IdType="pubmed">17003490</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, et al.A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011;122:111&#x2013;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Shepherd CE, Kril JJ, et al.Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathol Commun 2013;1:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046675</ArticleId><ArticleId IdType="pubmed">24252630</ArticleId></ArticleIdList></Reference><Reference><Citation>Cairns NJ, Neumann M, Bigio EH, et al.TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions. Am J Pathol 2007;171:227&#x2013;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1941578</ArticleId><ArticleId IdType="pubmed">17591968</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson Y, Kelley T, Mackenzie IR, et al.Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol 2007;113:521&#x2013;33</Citation><ArticleIdList><ArticleId IdType="pubmed">17219193</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Josephs KA, Amador-Ortiz C.. TDP-43 in the differential diagnosis of motor neuron disorders. Acta Neuropathol 2007;114:71&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">17569066</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita Y, Mizuno Y, Takatama M, et al.Anterior horn cells with abnormal TDP-43 immunoreactivities show fragmentation of the Golgi apparatus in ALS. J Neurol Sci 2008;269:30&#x2013;4</Citation><ArticleIdList><ArticleId IdType="pubmed">18206910</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, et al.TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008;319:1668&#x2013;72</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Millecamps S, Salachas F, Cazeneuve C, et al.SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: Genotype-phenotype correlations. J Med Genet 2010;47:554&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pubmed">20577002</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamaoka A, Arai M, Itokawa M, et al.TDP-43 M337V mutation in familial amyotrophic lateral sclerosis in Japan. Intern Med 2010;49:331&#x2013;4</Citation><ArticleIdList><ArticleId IdType="pubmed">20154440</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong HL, Wang JY, Sun YM, et al.Association between novel TARDBP mutations and Chinese patients with amyotrophic lateral sclerosis. BMC Med Genet 2010;11:8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821387</ArticleId><ArticleId IdType="pubmed">20082726</ArticleId></ArticleIdList></Reference><Reference><Citation>Therrien M, Dion PA, Rouleau GA.. ALS: Recent developments from genetics studies. Curr Neurol Neurosci Rep 2016;16:59.</Citation><ArticleIdList><ArticleId IdType="pubmed">27113253</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprovieri T, Ungaro C, Perrone B, et al.A novel S379A TARDBP mutation associated to late-onset sporadic ALS. Neurol Sci 2019;40:2111&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">31165305</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitcho MA, Bigio EH, Mishra M, et al.TARDBP 3&#x2032;-UTR variant in autopsy-confirmed frontotemporal lobar degeneration with TDP-43 proteinopathy. Acta Neuropathol 2009;118:633&#x2013;45</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783457</ArticleId><ArticleId IdType="pubmed">19618195</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Murrell JR, Horvath S, et al.TARDBP variation associated with frontotemporal dementia, supranuclear gaze palsy, and chorea. Mov Disord 2009;24:1843&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">19609911</ArticleId></ArticleIdList></Reference><Reference><Citation>Gelpi E, van der Zee J, Turon Estrada A, et al.TARDBP mutation p.Ile383Val associated with semantic dementia and complex proteinopathy. Neuropathol Appl Neurobiol 2014;40:225&#x2013;30</Citation><ArticleIdList><ArticleId IdType="pubmed">23692129</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno F, Rabinovici GD, Karydas A, et al.A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques. Acta Neuropathol Commun 2015;3:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382926</ArticleId><ArticleId IdType="pubmed">25853458</ArticleId></ArticleIdList></Reference><Reference><Citation>Spliet WG, Aronica E, Ramkema M, et al.Immunohistochemical localization of vascular endothelial growth factor receptors-1, -2 and -3 in the human spinal cord: Altered expression in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2004;30:351&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">15305980</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Beers DR, Wen S, et al.Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology 2009;72:1614&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">19414730</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Rodrigues MC, Hernandez-Ontiveros DG, et al.Amyotrophic lateral sclerosis: A neurovascular disease. Brain Res 2011;1398:113&#x2013;25</Citation><ArticleIdList><ArticleId IdType="pubmed">21632035</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Hern&#xe1;ndez-Ontiveros DG, Rodrigues MC, et al.Impaired blood-brain/spinal cord barrier in ALS patients. Brain Res 2012;1469:114&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pubmed">22750125</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou S, Lan YL, Wang H, et al.The potential roles of aquaporin 4 in amyotrophic lateral sclerosis. Neurol Sci 2019;40:1541&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">30980198</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler EA, Sengillo JD, Sullivan JS, et al.Blood-spinal cord barrier breakdown and pericyte reductions in amyotrophic lateral sclerosis. Acta Neuropathol 2013;125:111&#x2013;20</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3535352</ArticleId><ArticleId IdType="pubmed">22941226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Alterations of the blood-spinal cord barrier in sporadic amyotrophic lateral sclerosis. Neuropathology 2015;35:518&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pubmed">26242689</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamadera M, Fujimura H, Inoue K, et al.Microvascular disturbance with decreased pericyte coverage is prominent in the ventral horn of patients with amyotrophic lateral sclerosis. Amyotr Lat Scler Frontotemp Deg 2015;16:393&#x2013;401</Citation><ArticleIdList><ArticleId IdType="pubmed">25740316</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnenfeld H, Kascsak RJ, Bartfeld H.. Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol 1984;6:51&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">6368581</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Appel SH.. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 1990;47:1210&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">2122877</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelhardt JI, Tajti J, Appel SH.. Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 1993;50:30&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">8093428</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel JS, Engelhardt JI, Sikl&#xf3;s L, et al.Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 2004;55:221&#x2013;35</Citation><ArticleIdList><ArticleId IdType="pubmed">14755726</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S, Iguchi Y, Katsuno M, et al.Alterations in the blood-spinal cord barrier in TDP-43 conditional knockout mice. Neurosci Lett 2015;598:1&#x2013;5</Citation><ArticleIdList><ArticleId IdType="pubmed">25957558</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid B, Hruscha A, Hogl S, et al.Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proc Natl Acad Sci USA 2013;110:4986&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612625</ArticleId><ArticleId IdType="pubmed">23457265</ArticleId></ArticleIdList></Reference><Reference><Citation>Beuche W, Yushchenko M, Mader M, et al.Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuro-Report 2000;11:3419&#x2013;22</Citation><ArticleIdList><ArticleId IdType="pubmed">11095490</ArticleId></ArticleIdList></Reference><Reference><Citation>Demestre M, Parkin-Smith G, Petzold A, et al.The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol 2005;159:146&#x2013;54</Citation><ArticleIdList><ArticleId IdType="pubmed">15652414</ArticleId></ArticleIdList></Reference><Reference><Citation>Niebroj-Dobosz I, Janik P, Sokolowska B, et al.Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur J Neurol 2010;17:226&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pubmed">19796283</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K, Ohta Y, Nagai M, et al.Disruption of neurovascular unit prior to motor neuron degeneration in amyotrophic lateral sclerosis. J Neurosci Res 2011;89:718&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pubmed">21337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim GP, Backstrom JR, Cullen MJ, et al.Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J Neurochem 2002;67:251&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">8666998</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Moreno J, Dom&#xed;nguez R, et al.Inflammatory Gene expression in whole peripheral blood at early stages of sporadic amyotrophic lateral sclerosis. Front Neurol 2017;8:546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5645505</ArticleId><ArticleId IdType="pubmed">29081763</ArticleId></ArticleIdList></Reference><Reference><Citation>De Reuck J, Deramecourt V, Cordonnier C, et al.Detection of microbleeds in post-mortem brains of patients with frontotemporal lobar degeneration: A 7.0-Tesla magnetic resonance imaging study with neuropathological correlates. Eur J Neurol 2012;19:1355&#x2013;60</Citation><ArticleIdList><ArticleId IdType="pubmed">22642502</ArticleId></ArticleIdList></Reference><Reference><Citation>Wider C, Dickson DW, Stoessl AJ, et al.Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism Relat Disord 2009;15:281&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693935</ArticleId><ArticleId IdType="pubmed">18723384</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Castanedes-Casey M, Dickson DW.. Transactivation response DNA-binding protein 43 microvasculopathy in frontotemporal degeneration and familial Lewy body disease. J Neuropathol Exp Neurol 2009;68:1167&#x2013;76</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2783428</ArticleId><ArticleId IdType="pubmed">19816201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrer I. Brain banking In: Aminoff MJ, Daroff RB, eds. Encyclopedia of the Neurological Sciences, 2nd edition, vol. 1. Oxford: Oxford Academic Press; 2014:467&#x2013;73.</Citation></Reference><Reference><Citation>Andr&#xe9;s&#x2010;Benito P, Moreno J, Aso S, et al.Amyotrophic lateral sclerosis, gene deregulation in the anterior horn of the spinal cord and frontal cortex area 8: Implications in frontotemporal lobar degeneration. Aging 2017;9:823&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5391234</ArticleId><ArticleId IdType="pubmed">28283675</ArticleId></ArticleIdList></Reference><Reference><Citation>Andr&#xe9;s-Benito P, Gelpi E, Povedano M, et al.Gene expression profile in frontal cortex in sporadic frontotemporal lobar degeneration-TDP. Neuropathol Exp Neurol 2018;77:608&#x2013;27</Citation><ArticleIdList><ArticleId IdType="pubmed">29788265</ArticleId></ArticleIdList></Reference><Reference><Citation>Llad&#xf3; A, S&#xe1;nchez-Valle R, Re&#xf1;&#xe9; R, et al.Late-onset frontotemporal dementia associated with a novel PGRN mutation. J Neural Transm 2007;114:1051&#x2013;4</Citation><ArticleIdList><ArticleId IdType="pubmed">17417739</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Dickey CA, et al.Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci 2007;27:10530&#x2013;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6673167</ArticleId><ArticleId IdType="pubmed">17898224</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo A, Tapia L, Bamji SX, et al.Progranulin deficiency leads to enhanced cell vulnerability and TDP-43 translocation in primary neuronal cultures. Brain Res 2010;1366:1&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">20888804</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar-Singh S. Progranulin and TDP-43: Mechanistic links and future directions. J Mol Neurosci 2011;45:561&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207122</ArticleId><ArticleId IdType="pubmed">21863317</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang MC, Srinivasan K, Friedman BA, et al.Progranulin deficiency causes impairment of autophagy and TDP-43 accumulation. Exp Med 2017;214:2611&#x2013;28</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5584112</ArticleId><ArticleId IdType="pubmed">28778989</ArticleId></ArticleIdList></Reference><Reference><Citation>Belzil VV, Gendron TF, Petrucelli L.. RNA-mediated toxicity in neurodegenerative disease. Mol Cell Neurosci 2013;56:406&#x2013;19</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3791208</ArticleId><ArticleId IdType="pubmed">23280309</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentmann E, Haass C, Dormann D.. Stress granules in neurodegeneration&#x2013;lessons learned from TAR DNA binding protein of 43 kDa and fused in sarcoma. FEBS J 2013;280:4348&#x2013;70</Citation><ArticleIdList><ArticleId IdType="pubmed">23587065</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson P, Ivanov P.. tRNA fragments in human health and disease. FEBS Lett 2014;588:4297&#x2013;304</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339185</ArticleId><ArticleId IdType="pubmed">25220675</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, De Conti L, Stuani C, et al.Nuclear factor TDP-43 can affect selected microRNA levels. FEBS J 2010;277:2268&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pubmed">20423455</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Brindisi A, Giombi M, et al.TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through its C-terminal tail: An important region for the inhibition of cystic fibrosis transmembrane conductance regulator exon 9 splicing. J Biol Chem 2005;280:37572&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pubmed">16157593</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang IF, Wu LS, Chang HY, et al.TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem 2008;105:797&#x2013;806</Citation><ArticleIdList><ArticleId IdType="pubmed">18088371</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkening K, Leystra-Lantz C, Yang W, et al.Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins, and copper/zinc superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res 2009;1305:168&#x2013;82</Citation><ArticleIdList><ArticleId IdType="pubmed">19815002</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, D&#xf6;rk T, Zuccato E, et al.Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J 2001;20:1774&#x2013;84</Citation><ArticleIdList><ArticleId IdType="pmc">PMC145463</ArticleId><ArticleId IdType="pubmed">11285240</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, Polymenidou M, Cleveland DW.. TDP-43 and FUS/TLS: Emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 2010;19:R46-6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3167692</ArticleId><ArticleId IdType="pubmed">20400460</ArticleId></ArticleIdList></Reference><Reference><Citation>Tollervey JR, Curk T, Rogelj B, et al.Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci 2011;14:452&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3108889</ArticleId><ArticleId IdType="pubmed">21358640</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorpe JR, Tang H, Atherton J, et al.Fine structural analysis of the neuronal inclusions of frontotemporal lobar degeneration with TDP-43 proteinopathy. J Neural Transm 2008;115:1661&#x2013;71</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2789307</ArticleId><ArticleId IdType="pubmed">18974920</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, Lee VM, Trojanowski JQ.. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol Med 2011;17:659&#x2013;67</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202652</ArticleId><ArticleId IdType="pubmed">21783422</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Bilgutay A, Zhang YJ, et al.Tar DNA binding protein-43 (TDP-43) associates with stress granules: Analysis of cultured cells and pathological brain tissue. PLoS One 2010;5:e13250.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2952586</ArticleId><ArticleId IdType="pubmed">20948999</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano N, Catalani A, Lattante S, et al.ALS skin fibroblasts reveal oxidative stress and ERK1/2-mediated cytoplasmic localization of TDP-43. Cell Signal 2020;70:109591.</Citation><ArticleIdList><ArticleId IdType="pubmed">32126264</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Gumina V, Lenzi P, et al.Chronic stress induces formation of stress granules and pathological TDP-43 aggregates in human ALS fibroblasts and iPSC-motoneurons. Neurobiol Dis 2020;145:105051.</Citation><ArticleIdList><ArticleId IdType="pubmed">32827688</ArticleId></ArticleIdList></Reference><Reference><Citation>Riancho J, Castanedo-V&#xe1;zquez D, Gil-Bea F, et al.ALS-derived fibroblasts exhibit reduced proliferation rate, cytoplasmic TDP-43 aggregation, and a higher susceptibility to DNA damage. J Neurol 2020;267:1291&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pubmed">31938860</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaper DC, Adachi Y, Lazarou L, et al.Drosophila TDP-43 dysfunction in glia and muscle cells cause cytological and behavioural phenotypes that characterize ALS and FTLD. Hum Mol Genet 2013;22:3883&#x2013;93</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766182</ArticleId><ArticleId IdType="pubmed">23727833</ArticleId></ArticleIdList></Reference><Reference><Citation>Weihl CC, Temiz P, Miller SE, et al.TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008;79:1186&#x2013;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586594</ArticleId><ArticleId IdType="pubmed">18796596</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliv&#xe9; M, Janu&#xe9; A, Moreno D, et al.TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol 2009;68:262&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pubmed">19225410</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Donkervoort S, Dec E, et al.The multiple faces of valosin-containing protein-associated diseases: Inclusion body myopathy with Paget&#x2019;s disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. J Mol Neurosci 2011;45:522&#x2013;31</Citation><ArticleIdList><ArticleId IdType="pubmed">21892620</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>